JP Patent

JP6788600B2 — がんを治療するための、ｐｄ−１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ

Assigned to Merck Sharp and Dohme LLC · Expires 2020-11-25 · 5y expired

What this patent protects

Patent listed against lenvatinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
JP6788600B2
Jurisdiction
JP
Classification
—
Expires
2020-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.